Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.71 USD
+0.01 (1.43%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $0.71 0.00 (0.00%) 7:42 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Spruce Biosciences, Inc. (SPRB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$4.20 | $10.00 | $2.00 | 500.00% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Spruce Biosciences, Inc. comes to $4.20. The forecasts range from a low of $2.00 to a high of $10.00. The average price target represents an increase of 500% from the last closing price of $0.70.
Analyst Price Targets (5 )
Broker Rating
Spruce Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 2.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, two are Strong Buy, representing 28.57% of all recommendations. A month ago, Strong Buy represented 28.57%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 6 | 5 |
Buy | 0 | 0 | 0 | 1 | 1 |
Hold | 5 | 5 | 5 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.43 | 2.43 | 2.43 | 1.14 | 1.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/14/2024 | Guggenheim Securities | Evan Wang | Strong Buy | Hold |
3/14/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Hold |
3/14/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Not Available | Hold |
3/14/2024 | LadenburgThalmann | Aydin Huseynov | Strong Buy | Hold |
3/14/2024 | JMP Securities | Jonathan Wolleben | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.43 |
ABR (Last week) | 2.43 |
# of Recs in ABR | 7 |
Average Target Price | $4.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.32 |